Brief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
24/08/2026 23:58
BRIEF-Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics Aug 24 (Reuters) - Barinthus Biotherapeutics PLC 2ABy.F:
BARINTHUS BIO PROVIDES UPDATE ON PROPOSED COMBINATION WITH CLYWEDOG THERAPEUTICS
BARINTHUS BIOTHERAPEUTICS - SCHEME EXCHANGE RATIO SET AT 0.111 FOR BARINTHUS BIO AND CLYWEDOG MERGER
BARINTHUS BIOTHERAPEUTICS - SCHEME OF ARRANGEMENT TO BECOME EFFECTIVE SEPT 3, 2026; BARINTHUS BIO ADSS TO CEASE NASDAQ TRADING
Further company coverage: [2ABy.F]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing